Advances, setbacks seen in breast cancer research

The fight against breast cancer, the second most dangerous after lung cancer, is making progress, but has experienced a number of setbacks, scientists said.

The most interesting progress was reported in a new study unveiled here Sunday that found that a new agent derived from a marine sponge can extend the survival rates of women with locally recurrent or metastatic breast cancer who already received extensive standard therapy.

The synthetic component called eribulin mesylate mimics a component found naturally in sponges and can prevent cell division, which causes cells to self-destruct, said study authors who presented their findings at the annual American Society of Clinical Oncology conference here.

In a randomized international trial, British researchers assessed the survival rates of 762 patients, treated either with eribulin or another therapy, almost always chemotherapy, and found the new therapy extended median overall survival by about 2.5 months.

"Until now, there hasn't been a standard treatment for women with such advanced breast cancer. For those who have already received all of the recognized treatments, these are promising results," said lead study author Christopher Twelves.

"These findings may establish eribulin as a new, effective option for women with heavily pre-treated metastatic breast cancer," said Twelves, head of the Clinical Cancer Research Groups at the Leeds Institute of Molecular Medicine in Britain.

The most frequently reported adverse effects among patients treated with eribulin were fatigue (53.7 percent), low white blood cell counts (51.7 percent), hair loss (44.5 percent) and numbness and tingling in different parts of the body (34.6 percent).

Serious adverse effects were reported for 25 percent of patients, the researchers said.

More than one million women a year are diagnosed with breast cancer worldwide, according to international statistics.

Approximately 50 percent of them are expected to develop recurrent or metastatic disease within 15 years of their first diagnosis.

Only one in five women with metastatic breast cancer survives longer than five years.

In the United States, an estimated 155,000 women are currently living with metastatic breast cancer, and that number is projected to increase to 162,000 by 2011.

"Women with advanced breast cancer are in critical need of new treatment options," said Alton Kremer, head of clinical development for oncology at Eisai Inc., the developer of eribulin

"In this study, eribulin has shown an improvement in survival, and if approved by health authorities, it may offer patients a new treatment option at this stage of the disease," he added

An application for marketing the drug was granted priority review status by the US Food and Drug Administration last month.

Another study presented at the conference showed that partial targeted irradiation of affected breasts can be effective. But some researchers reported setbacks.

A study by the John Wayne Cancer Institute in Santa Monica, Calififornia has concluded that removing additional underarm lymph nodes to look for more breast cancer cells in women with limited disease spread does not improve survival.

An observational trial of more than 5,500 women with early-stage breast cancer who had breastsparing surgery showed that using immunohistochemistry to detect hidden micrometastases in sentinel lymph nodes and bone marrow does not predict overall survival and should not be used to guide treatment decisions.

Yet another report found that shows that the characteristics of tumors in women with metastatic breast cancer often change when cancer spreads to the liver, requiring a change in therapy in more than 12 percent of patients.

Life and Style
ebookNow available in paperback
ebooks
ebookA delicious collection of 50 meaty main courses
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
SPONSORED FEATURES

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    SThree: Trainee Recruitment Consultant - Bristol

    £18000 - £23000 per annum + Uncapped OTE: SThree: SThree Trainee Recruitment C...

    Recruitment Genius: Purchasing Administrator - Chinese Speaking

    £17000 - £24000 per annum: Recruitment Genius: This rapidly growing company is...

    Recruitment Genius: Start a Career as a Financial Markets Trader

    £40000 - £100000 per annum: Recruitment Genius: Become a professional Trader a...

    Recruitment Genius: Software Implementation Consultant

    £45000 - £50000 per annum: Recruitment Genius: This software company specialis...

    Day In a Page

    Giants Club: After wholesale butchery of Idi Amin's regime, Uganda’s giants flourish once again

    Uganda's giants are flourishing once again

    After the wholesale butchery of Idi Amin's regime, elephant populations are finally recovering
    The London: After 350 years, the riddle of Britain's exploding fleet is finally solved

    After 350 years, the riddle of Britain's exploding fleet is finally solved

    Archaeologists will recover a crucial item from the wreck of the London which could help shed more light on what happened in the vessel's final seconds
    Airbus has patented a jet that could fly from London to New York in one hour

    Airbus has patented a jet that could fly from London to New York in one hour

    The invention involves turbojets and ramjets - a type of jet engine - and a rocket motor
    10 best sun creams for kids

    10 best sun creams for kids

    Protect delicate and sensitive skin with products specially formulated for little ones
    Tate Sensorium: New exhibition at Tate Britain invites art lovers to taste, smell and hear art

    Tate Sensorium

    New exhibition at Tate Britain invites art lovers to taste, smell and hear art
    Ashes 2015: Nice guy Steven Finn is making up for lost time – and quickly

    Nice guy Finn is making up for lost time – and quickly

    He was man-of-the-match in the third Test following his recall to the England side
    Ashes 2015: Remember Ashton Agar? The No 11 that nearly toppled England

    Remember Ashton Agar?

    The No 11 that nearly toppled England
    Turkey-Kurdish conflict: Obama's deal with Ankara is a betrayal of Syrian Kurds and may not even weaken Isis

    US betrayal of old ally brings limited reward

    Since the accord, the Turks have only waged war on Kurds while no US bomber has used Incirlik airbase, says Patrick Cockburn
    VIPs gather for opening of second Suez Canal - but doubts linger over security

    'A gift from Egypt to the rest of the world'

    VIPs gather for opening of second Suez Canal - but is it really needed?
    Jeremy Corbyn dresses abysmally. That's a great thing because it's genuine

    Jeremy Corbyn dresses abysmally. That's a great thing because it's genuine

    Fashion editor, Alexander Fury, applauds a man who clearly has more important things on his mind
    The male menopause and intimations of mortality

    Aches, pains and an inkling of mortality

    So the male menopause is real, they say, but what would the Victorians, 'old' at 30, think of that, asks DJ Taylor
    Man Booker Prize 2015: Anna Smaill - How can I possibly be on the list with these writers I have idolised?

    'How can I possibly be on the list with these writers I have idolised?'

    Man Booker Prize nominee Anna Smaill on the rise of Kiwi lit
    Bettany Hughes interview: The historian on how Socrates would have solved Greece's problems

    Bettany Hughes interview

    The historian on how Socrates would have solved Greece's problems
    Art of the state: Pyongyang propaganda posters to be exhibited in China

    Art of the state

    Pyongyang propaganda posters to be exhibited in China
    Mildreds and Vanilla Black have given vegetarian food a makeover in new cookbooks

    Vegetarian food gets a makeover

    Long-time vegetarian Holly Williams tries to recreate some of the inventive recipes in Mildreds and Vanilla Black's new cookbooks